A solid phase extraction-liquid chromatographic-tandem mass spectrometry method for determination of concentrations of GDC-0941, a small molecule class I phosphatidylinositide 3-kinase inhibitor, to support clinical development

Journal of Pharmaceutical and Biomedical Analysis

Volumn 61, Issue , 2012, Pages 1-7

  Ding, X ^a   Morrison, G ^a   Dean, B ^a   Hop, C E C A ^a   Tobler, L ^b   Percey, S ^b   Meng, M ^b   Reuschel, S ^b   West, D A ^a   Holden, S ^a   Ware, J A ^a  

^a GENENTECH INC   (United States)

^b Northwest Toxicology Inc   (United States)

Author keywords

96 Well SPE; Class I phosphatidylinositide 3 kinase (PI3K); GDC 0941; Human plasma; LC MS MS

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PICTRELISIB;

ARTICLE; CALIBRATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG STABILITY; HUMAN; LIQUID CHROMATOGRAPHY; PLASMA; PRIORITY JOURNAL; QUALITY CONTROL; REVERSED PHASE LIQUID CHROMATOGRAPHY; ROOM TEMPERATURE; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

CHROMATOGRAPHY, LIQUID; FEMALE; HUMANS; INDAZOLES; MALE; PHOSPHATIDYLINOSITOL 3-KINASE; REPRODUCIBILITY OF RESULTS; SOLID PHASE EXTRACTION; SULFONAMIDES; TANDEM MASS SPECTROMETRY;

EID: 84856099416     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2011.11.005     Document Type: Article

References (14)

1. Sarker D., Kristeleit R., Mazina K.E., Ware J.A., Yan Y., Dresser M., Derynck M.A., de Bono J.S. A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphatidylinositol 3-kinase (PI3K) inhibitor GDC-0941. J. Clin. Oncol. ASCO Annu. Meet. Proc. 2009, 27:3538.
2. Multiple Clinical Trials Listed at http://clinicaltrials.gov/ct2/results?term=gdc-0941.
3. O'Brien C., Wallin J.J., Sampath D., GuhaThakurta D., Savage H., Punnoose E.A., Guan J., Berry L., Prior W.W., Amler L.C., Belvin M., Friedman L.S., Lackner M.R. Predictive biomarker of sensitivity to phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin. Cancer Res. 2010, 16:3670-3683.
4. Salphati L., Wong H., Belvin M., Bradford D., Edgar K.A., Prior W.W., Sampath D., Wallin J.J. Pharmacokinetic-pharmocodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. Drug Metab. Dispos. 2010, 38:1436-1442.
5. Raymaud F.I., Eccles S.A., Patel S., Alix S., Box G., Chuckowree I., Folkes A., Gowan S., Brandon A.D.H., Stefano F.D., Hayes A., Henley A.T., Lensun L., Pergl-Wilson G., Robson A., Saghir N., Zhyvoloup A., McDonald E., Sheldrake P., Shuttleworth S., Valenti M., Wan N.C., Clarke P.A., Workman P. Biological properties of potent inhibitors of class I phosphatidylinositol 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol. Cancer Ther. 2009, 8:1725-1738.
6. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., Miliaresis C., Rodgers L., McCombie R., Bigner S.H., Giovanella B.C., Ittmann M., Tycko B., Hibshoosh H., Wigler M.H., Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science 1997, 275:1943-1947.
7. Steck P.A., Pershouse M.A., Jasser S.A., Yung W.K.A., Lin H., Ligon A.H., Langford L.A., Baumgard M.L., Hattier T., Davis T., Frye C., Hu R., Swedlund B., Teng D.H.F., Tavtigian S.V. Identification of a candidate tumor suppressor gene, MMACI, at chromosome 10q23.3 that i8s mutated in multiple advanced cancers. Net Gene 1997, 15:356-362.
8. Staal S.P. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc. Natl. Acad. Sci. U.S.A. 1987, 84:5034-5037.
9. Bellacosa A., Defeo D., Godwin A.K., Bell D.W., Cheng J.Q., Altomare D.A., Wan M.H., Dubeau L., Scambia G., Masciullo V., Ferrandina G., Panici P.B., Mancuso S., Neri G., Testa J.R. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int. J. Cancer 1995, 64:280-285.
10. Cheng J.Q., Godwin A.K., Bellacosa A., Taguchi T., Franke T.F., Hamilton T.C., Tsichlis P.N., Testa J.R. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinase, is amplified in human ovarian carcinomas. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:9267-9271.
11. Aoki M., Batista O., Bellacosa A., Tsichlis P., Vogt P.K. The Akt kinase: molecular determinants of oncogenicity. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:14950-14955.
12. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., Yan H., Gazdar A., Powell S.M., Riggins G.J. High frequency of mutations of the PI3KCA gene in human cancers. Science 2004, 304:554.
13. Buchman K.E., Argani P., Silliman Y., Ptak J., Szabo S., Konishi H., Karakas B., Blair B.G., Lin C. The PI3KCA gene is mutated with high frequency in human breast cancers. Cancer Biol. Ther. 2004, 3:772-775.
14. Viswanathan C.T., Bansal S., Booth B., DeStefano A.J., Rose M.J., Sailstad J., Shah V.P., Skelly J.P., Swann P.G., Weiner R. Workshop/conference report - quantitative bioanalysis methods validation and implementation: best practices for chromatographic and ligand binding assays. AAPS J. 2007, 9:E30-E42.